Scinai Reports Q1 Results, Completes Strategic CDMO Acquisition with $6.2M Bargain Gain

summarizeSummary

Scinai reported Q1 2026 results, turning a profit due to a $6.2 million non-cash gain from completing the Recipharm Israel acquisition, which also boosted cash and expanded its CDMO business.

check_boxKey Events

• Q1 2026 Financial Results

  Reported a net income of $3.6 million, a significant improvement from a $1.6 million loss in Q1 2025, primarily due to a $6.2 million non-cash bargain purchase gain from the Recipharm Israel acquisition. Operating loss, however, widened to $2.5 million from $1.6 million year-over-year.

• Strategic CDMO Acquisition Completed

  Finalized the acquisition of Recipharm Israel, expanding its contract development and manufacturing organization (CDMO) platform. The acquisition added approximately $2.8 million in cash and $3.6 million in manufacturing infrastructure and equipment.

• Cash Position Improved

  Cash, cash equivalents, and restricted cash increased to $3.1 million as of March 31, 2026, up from $1.8 million at the end of 2025, bolstered by the acquired cash.

• Non-Dilutive Funding Progress

  Advanced multiple grant applications in Poland and Israel to support its therapeutic pipeline and CDMO expansion, with several decisions expected in the second half of 2026.

auto_awesomeAnalysis

Scinai Immunotherapeutics reported Q1 2026 financial results, showing a net profit driven by a significant non-cash bargain purchase gain from the completed acquisition of Recipharm Israel. This acquisition materially expanded the company's CDMO platform, adding $2.8 million in cash and $3.6 million in manufacturing infrastructure, which is critical for a company facing going concern doubts and Nasdaq delisting threats. While operating losses widened, progress on non-dilutive grant funding initiatives offers a potential lifeline for future development programs.